Mode
Text Size
Log in / Sign up
N/A N=33 Supportive Care

Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy

Diabetic Foot Ulcers

Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Ease of Use Assessment — 0; 3; 14; 13 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
V.A.C. Negative Pressure Wound Therapy System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
KCI USA, Inc
Primary completion
Jun 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Ease of Use Assessment
0; 3; 14; 13; 0; 1

Summary

The study is aimed at evaluating the clinician's perceived ease of using the V.A.C. GranuForm bride dressing and the patients perceived level of comfort during the dressing wear.

Eligibility Criteria

Inclusion Criteria

  • Male or Female subjects must be ≥ 18 years of age
  • Subject is willing and able to provide written informed consent and comply with protocol required procedures
  • Subject has a calcaneal, dorsal or plantar diabetic foot ulcer no greater than a Grade 2 on the Wagner Grading System for which ActiV.A.C.® Therapy has been prescribed and requires off loading of the SensaT.R.A.C. PadTM
  • Subject has a foot ulcer that is ≥ 1.5cm2 but no greater than 84 cm2
  • Female subject that is willing to use an effective method of contraception for the duration of the study, is permanently sterilized, or post-menopausal as defined by cessation of menses for at least twelve (12) months prior to enrollment. Acceptable means of contraception is defined as use of Birth control pills, Depo Provera® , Norplant® , IUD (intrauterine device), Diaphragm with spermicide, Condom with spermicide

Exclusion Criteria

  • Subject's wound measures > 84 cm2
  • Presence of untreated cellulitis
  • Presence of untreated or refractory osteomyelitis (including untreated necrotic bone, non-viable tissue and infected bone)
  • History of radiation to the wound area
  • History of thermal injury in the wound area
  • Known hypersensitivity to any disposable component of the V.A.C.® Therapy system
  • Necrotic tissue with eschar present that cannot be debrided prior to subject enrollment in the study
  • Subject is exhibiting active signs and symptoms of infection of the wound(i.e. increased redness or erythema, increased pain, warmth, purulent drainage)
  • Past or current enrollment in this clinical study or any other clinical study within 30 days
  • Female Subject who is pregnant or is unwilling to use acceptable means of contraception during the duration of her participation in the study
  • Subject exhibits significant peri-wound issues that in the opinion of the investigator can interfere with the study assessments
  • Subject is unable to co-operate with study assessments or has a history of non-compliance with off-loading modalities or has a foot deformity that in the opinion of the investigator does not allow for appropriate dressing application or off loading placement.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00847730). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search